Research-only notice

Prepared by: Research Desk. Sources are linked for verification.
CognitivePepti summarises published research and public regulatory records about peptides studied in laboratories. All content is provided for research and educational purposes only. It is not intended for human use and it is not medical advice.
What this site does not provide
- Medical advice, diagnosis or guidance on the use of any substance in people or animals.
- Instructions on preparation, administration, amounts or schedules.
- Claims that any research compound is safe or effective in people.
Research-use-only materials
Materials labelled "research use only" are intended for laboratory research. They are not approved medicines. A supplier's certificate of analysis describes a batch; it says nothing about suitability for any use. Where a compound also exists as a regulator-approved product, that approval covers the specific product and its labelled use only.
Evidence and its limits
Many findings summarised here come from cell or animal studies, which often do not carry over to people. Each page links its primary sources so that readers can check the original records.
Health questions
This site does not answer individual health questions.
Paid links
Some pages carry paid links to a research supplier. See the affiliate disclosure.
Contact
Corrections and questions: info@zvezdaff.com.
Last updated: 21 October 2026.
More from CognitivePepti
Cognition-related peptides in research: Semax, Selank and DSIP compared
A side-by-side research reference on Semax, Selank and DSIP: where they came from, their sequences, the studies on record, proposed mechanisms and FDA status.
Selank: the tuftsin analogue and its research record
Selank is a synthetic heptapeptide built on the tuftsin sequence. This page summarises its origins, published preclinical work, regulatory record and remaining gaps.
DSIP (delta sleep-inducing peptide): fifty years of an unresolved peptide
DSIP was isolated from rabbit brain in 1977, yet its receptor and mechanism remain unresolved. A summary of the early studies, open questions and the 2026 FDA advisory agenda.


